Efficacy and safety of tolvaptan for refractory fluid collection and edema in the terminal cancer patients.

ABSTRACT:

Objective

Tolvaptan, a vasopressin V₂ receptor antagonist, is an oral diuretic. Patients with terminal cancer develop marked fluid retention, and oral diuretics other than tolvaptan have been used as treatments without clear therapeutic effects. Herein, we aimed to study the efficacy and safety of tolvaptan in patients with terminal cancer.

Methods

Tolvaptan was administered at a dose of 7.5 mg/day to 29 patients (median, 72 years) between August 2017 and February 2020. The duration of tolvaptan treatment ranged from 1 to 85 days (mean, 18.5 days).

Results

Median albumin (Alb) and transthyretin (TTR) levels on admission were 2.3 g/dL (1.2-4.2 g/dL) and 8.9 mg/dL (2.1-38.2 g/dL), respectively. Median Alb and TTR levels 1 month after treatment initiation rema

SUBMITTER: Tsuzuki N 

PROVIDER: S-EPMC9923446 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature